Clinical trial site selection is broken. We fixed it.
Atlas compresses six weeks of investigator feasibility work into seconds ranking trial sites worldwide by eight evidence backed factors across six public registries.
Site selection is the quiet reason trials slip.
Feasibility teams manually cross-reference registries, publications, and CRO intel. By the time a shortlist lands, the window has closed.
Six weeks becomes seconds.
Describe the trial in plain English. A planner agent extracts filters, a search agent fans out across twelve public registries, and a rating agent scores the shortlist against eight factors — returning an evidence-cited dossier in seconds.
- 1Querynatural language brief
- 2PlannerMastra · gpt-5
- 3SearchMastra · gpt-5
- 4Profile fan-out12 public registries
- 5RatingMastra · gpt-5
- 6Dossierevidence-cited shortlist
Eight factors, no black box.
Every candidate score decomposes into explainable, evidence-backed dimensions. Click any factor in the product to see the underlying citations, CT.gov IDs, and publication lineage.
- Factors
- 8
- Registries
- 6
- Indication match96
- Phase experience88
- Enrollment velocity85
- Publication velocity94
- Capacity signal91
- Institutional track84
- Responsiveness95
- Regulatory rigor100
Six registries. Citable. Reproducible.
No proprietary scraping, no opaque scoring — just the same public sources regulators and investigators already trust.
Find the investigators nobody's called yet.
Velocity deltas and capacity signals surface high-performing PIs before they hit every CRO's shortlist — often in under-enrolled regions.
The math is uncomfortable.
Drag the slider. At typical sponsor volumes, Atlas pays for itself within the first protocol.
- CRO fees avoided
- $360K
- Analyst time freed
- 72 wks
- Atlas cost
- $180K
- Net savings
- $468K
Your next PI is already in the data.
Stop paying CROs to re-read the same public registries. Ship a feasibility shortlist before lunch.